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Background
Substance use disorder (SUD) is a major global health
problem, which has increased notably in the last few years
[1]. In Australia, a recent publication reported that one in
200 people in the general population received treatment
for substance use in 2014–15, which represents a 6% in-
crease from the previous year [2]. Although SUD is fre-
quently described as a chronic and relapsing condition,
favourable long-term outcomes are consistently associated
with alcohol and other drug (AOD) treatment completion
[3]. However, failure to complete treatment, or “drop-out”,
is very common in both inpatient and outpatient treat-
ment services [4, 5].
According to a systematic review of the literature, one
of the major risk factors of drop-out from AOD treatment
is cognitive impairment [6]. Over the last two decades,
neuropsychological research has consistently shown that
substance use is associated with a significant degree of im-
pairment in cognitive functioning. Whilst specific aspects
of cognitive functioning may predate and influence the
initiation of AOD use [7], increased substance use results
in a greater degree of impairment [8, 9]. That is, there is a
strong association between the quantity and duration of
AOD use and the degree of cognitive dysfunction. Cogni-
tive deficits in individuals with SUD may be further exac-
erbated by the presence of common comorbidities such as
traumatic brain injury and psychiatric disorders [10, 11].
Although partial recovery of cognitive impairment may
occur after immediate cessation of AOD use, many cogni-
tive deficits fail to recover following withdrawal and ab-
stinence [12, 13]. For example, it has been estimated that
approximately 50–80% of recently detoxified individuals
with SUD are cognitively impaired when assessed with the
Montreal Cognitive Assessment [14–17].
In individuals with SUD, the most prominent cognitive
deficits are seen in executive functioning (EF) [9, 18]. EF
abilities (such as working memory, planning and organisa-
tional skills, reasoning, and self-regulation) are mediated by
the frontal cortex, an area of the brain that is particularly
vulnerable to substance-related impairment [19]. Common
AOD treatment interventions, including counselling and
psychoeducation, are heavily reliant on intact EF abilities in
order to identify, promote and achieve successful behav-
ioural change [20, 21]. Thus, EF impairment significantly
predicts treatment drop-out and relapse [22–24].
Given the clinical relevance of EF deficits in the SUD
population, it has been proposed that evidence-based
neuropsychological interventions may be particularly
useful in improving treatment outcomes and facilitating
recovery [25–27]. Traditionally, cognitive remediation
(CR) interventions have been inspired by two main the-
oretical perspectives; restoration and compensation [28].
Restorative (or “bottom-up”) approaches attempt to re-
pair impaired cognitive skills directly by using “drill and
practice” exercises, and have typically been used in men-
tal health populations [29]. On the other hand, compen-
satory (or “top-down”) techniques circumvent the deficit
with reliance on intact cognitive skills and environmen-
tal and prosthetic supports, and are frequently employed
in acquired brain injury rehabilitation [30].
In the SUD literature, the majority of existing studies
have predominantly used a restorative approach to CR, gen-
erally via “drill and practice” computerised tasks [31–35].
Whilst the results of these studies suggest that “drill and
practice” leads to improvement on performance-based
measures of EF, whether these improvements also lead to
demonstrated improvement in everyday functioning is un-
clear. Performance-based measures of EF show limited eco-
logical validity and do not relate to everyday functioning as
well as inventory-based measures [36, 37]. Furthermore,
there is intense debate as to the precise mechanisms of
“drill and practice” training and the ability of this approach
to transfer trained skills into real-world improvements,
most notably treatment retention and recovery [25, 38].
In comparison, meta-analytical studies and systematic
reviews have shown that compensatory CR approaches
have significantly stronger effects not only on global
cognition, but also on real-world functioning, than pro-
grams that focus only on restorative techniques in other
cognitively impaired populations [30, 39, 40]. Whilst only
a limited number of studies have examined the effects of
compensatory CR in the SUD population, preliminary find-
ings are promising [41–44]. In a sample of patients with
severe alcohol-related brain damage, an intensive rehabili-
tation program incorporating compensatory CR strategies
resulted in an 85% reduction in subsequent acute admis-
sions [44]. Two other studies have assessed the efficacy of
Goal Management Training (GMT), a predominantly
“top-down” CR technique, combined with mindfulness
meditation [41, 43]. Results revealed that GMT not only
improved performance on tasks of working memory, im-
pulsivity, and decision making, but also on an ecologically
valid measure of goal-directed behaviour, suggesting that
the intervention relates to improvements in daily life activ-
ities [43]. Another recent study showed that residents in
community AOD treatment who received a combination
of restorative and compensatory CR showed improvement
on a performance-based measure of inhibition, as well as
inventory-based measures of EF, impulsivity, self-control
and quality of life [42]. Overall, these initial results support
the argument that a “top-down” approach to CR may
translate to real-world situations because people are better
able to transfer skills from the training environment into
their daily lives and that teaching such strategies helps pa-
tients compensate for the effects of persistent cognitive im-
pairments on functioning [45, 46].
A major limitation in the existing literature is that
there have been no randomised trials of compensatory
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CR in the SUD population. Another difficulty of the lit-
erature is that studies often exclude participants with
common comorbidities such as traumatic brain injury
and psychiatric comorbidities. This ultimately affects the
generalisability of results. In addition, many studies have
relied on performance-based measures of EF rather than
more ecologically valid EF measures, which have been
shown to be better predictors of real-world functioning
and treatment success [47]. Finally, previous SUD
literature has not followed-up the long-term effects of
compensatory CR, such as treatment retention and
recovery. Given findings of its success in improving
functional outcomes in other cognitively impaired
groups, we propose that compensatory CR aimed at
improving EF is likely to be a beneficial adjunctive
intervention to boost AOD treatment efficacy and
long-term outcomes.
The current study
The study will aim to examine the effectiveness of adding a
CR intervention to TAU on two primary outcomes, being:
1. A self-report inventory of executive functioning;
and
2. Treatment retention
The study will also assess the impact of CR in addition
to TAU on a number of secondary outcomes:
1. AOD use
2. Health service utilisation
3. Functional goal attainment
4. Quality of life
5. Client satisfaction with treatment
6. Performance-based measures of EF
7. Economic analysis
The study will be conducted as a stepped wedge ran-
domised cluster trial. Stepped wedge designs are increas-
ingly being utilised in the evaluation of interventions
within routine treatment services and are recommended
where there are limited numbers of clusters [48–50].




The research program will be conducted at ten residen-
tial treatment facilities run by non-governmental organi-
sations in NSW, Australia. All organisations will be
abstinence-based however a portion of residents may be
prescribed medications or opioid substitution treatments
(OST) (e.g. methadone). Limited leave from the residen-
tial facilities, close observation by staff and other
residents, and random urine tests will ensure abstinence
from substances while participants are enrolled in treat-
ment programs. Services that accommodate at least 15
residents and have a minimum project duration of 10
weeks will be invited to participate in the study.
Ethics approval and consent to participate
The Macquarie University Human Research Ethics Com-
mittee (HREC (Medical Science)) approved the research
to trial (Reference Number 5201800077), which is regis-
tered with the Australian New Zealand Clinical Trials
Registry (ACTRN12618001190291). All participants will
provide written informed consent to a research officer
prior to participating in the trial. Consent will be pro-
vided separately for access to linked healthcare data
through the Centre for Health Record Linkage. Partici-
pants will also able to request to withdraw from the
study at any point during their participation (data collec-
tion, intervention or both).
Study design
The proposed study will be conducted as a prospective
stepped wedge cluster randomised trial, where randomisa-
tion will occur at the cluster level. The design involves ran-
dom and sequential crossover of clusters from TAU to CR
until all clusters have implemented CR (Table 1). TAU was
selected as the comparator condition as the CR interven-
tion must be demonstrated to be effective above and be-
yond what residential AOD services are currently offering
in order to be useful as an adjunct treatment. There will be
four six-week phases of either TAU or CR, interspersed by
two-week test phases, at each of the ten sites. The order in
which the sites receive cognitive remediation will be gener-
ated by an independent statistician using computer-gener-
ated randomisation. After the initial two-week assessment
phase (weeks 1–2), all clusters will undergo 6 weeks of
treatment as usual (weeks 3–8). Following the second
two-week assessment phase (weeks 9–10) clients at the
three sites randomised to start first will receive CR for a
period of 6 weeks (weeks 11–16), then this treatment will
continue for the life of the study. After the next two-week
test phase (weeks 17–18), another 3 sites will be randomly
selected to commence CR, and so on until all services have
provided CR. Six weeks after the final post-intervention
phase (weeks 33–34) an additional two-week testing phase
will be allocated for follow-up (weeks 41–42). CONSORT
procedures will be followed including using an intention to
treat analysis [51].
The estimated number of participants is based on
prior research in NSW residential drug and Alcohol
Treatment [42]. Discharge refers to the discharge of par-
ticipants from the residential treatment service (either
through completing the program or self-discharge/drop
out before the completion of the program). Attrition
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refers to drop-out from the study or otherwise being
non-contactable following discharge from the treatment
service.
1. Each site will start with n = 20 participants on
average;
2. Within a single cohort, there will be:
a. a 40% discharge rate over each six-week TAU/
CR phase plus two-week test phase;
b. a 65% discharge rate over the following 2
months;
c. an 80% discharge rate over the following 4
months;
d. a 90% discharge rate over the following 6
months; and
e. a 95% discharge rate over the following 8
months;
3. New clients will enter a service at the same rate as
other clients leave the service;
4. If a client enters a service during a TAU/CR phase,
they will delay their participation in the trial until
the next test phase;
5. Some clients will participate in more than one
CR phase;
6. All participants who have completed at least one
TAU/CR phase will be eligible for follow-up testing,
which will occur at test phases 3, 4, 5 and 6.
7. If a participant has had a CR phase they are
ineligible for TAU follow-up.
8. If a participant has had more than one CR phase
they will still be eligible for CR follow-up
9. Follow-up attrition rates have been estimated to be:
a. 65% attrition at two-month follow up
b. 75% attrition at four-month follow up
c. 85% attrition at six-month follow up
d. 90% attrition at eight-month follow up
Participants
All participants will be attending residential AOD treat-
ment programs in NSW. It is expected that over the
course of the study approximately 440 participants will
be recruited, with 40% expected to drop out within the
first 8 weeks. Based on figures from 2014 to 15, we an-
ticipate that the majority of participants will be seeking
treatment for the four most common principal drugs of
concern; alcohol, cannabis, amphetamines and heroin
[2]. All participants will provide informed written con-
sent and will be aged 18 years or older.
Inclusion and exclusion criteria
All participants attending the residential programs will
be invited to participate in the study. Exclusion criteria
will be kept to a minimum to ensure that the study can
examine the effectiveness of using CR in addition to
TAU within a “real world” setting. For example, trau-
matic brain injury and psychiatric comorbidities are
common in individuals with AOD use [10, 11], therefore
these factors will not be part of the exclusion criteria in
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order to make the sample as representative as possible.
Similarly, while the residential treatment services will be
abstinence-based, a portion of clients will be prescribed
OST or other medication, and these participants will
also be included.
CR intervention
The manualised Cognitive Remediation in Drug and Alco-
hol Services (CRiDAS) program will be used for CR,
which consists of 12 one-hour group-based sessions that
will take place across 6 weeks (two sessions per week).
Each session will be dedicated to strategy training, which
includes traditional instructional pedagogical approaches,
group discussion/reflection and exercises to demonstrate
concepts. The CR intervention was developed with a
strong emphasis on the training of EF in view of the find-
ing that EF is particularly impaired in an AOD treatment
population. Barkley’s evolutionary model of EF [52, 53]
was used to structure a large part of the program. The CR
program will use a “top-down” approach, including train-
ing in compensatory strategy use with a particular em-
phasis on EF. The modules cover the following topics:
brain functioning, attention, memory, visual and verbal
working memory, emotion regulation, decision-making
and problem-solving. Facilitators will be staff of the resi-
dential AOD treatment sites who will undergo training to
administer the intervention, and will be chosen by service
management on the basis of a minimum skillset relevant
to program delivery. Facilitators will be trained immedi-
ately prior to introducing the intervention, to prevent staff
from utilising CR techniques during phases of TAU.
Intervention facilitators will take attendance for each
module of the intervention in order to monitor adher-
ence and dose of the intervention. An independent re-
searcher/clinician will use the CRiDAS treatment fidelity
measure (to be developed) to measure fidelity via audio/
video recordings of 10% of the sessions at each site.
Assessment measures
See Table 2 for an outline of the timeline of assessment
measures. To provide an estimate of the overall level of
premorbid intellectual functioning, the Test of Premor-
bid Functioning [54] will be administered once only, at
the first test phase. One primary outcome measure will
be an inventory-based measure of EF, as previous find-
ings have shown that inventory-based assessment is
more strongly associated with real-world functioning
outcomes in SUD than performance-based assessment
[36]. Given the high rates of treatment drop-out in resi-
dential AOD treatment services, another primary out-
come measure will be the length of treatment retention,
measured as time in treatment as a proportion of pro-
gram duration [4]. This is because the program duration
may vary across services. Secondary outcome measures
will evaluate substance use severity, health service util-
isation, individual goal-attainment, quality of life, treat-
ment satisfaction, and performance-based measures of
EF. An economic analysis will also be undertaken to evalu-
ate the costs associated with delivering CR versus TAU.
Data collection will be facilitated by research assistants
blinded to the randomised condition, that is, whether or
not a site has implemented cognitive remediation.
Outcome measures will be taken at intake, the test
phases (2 week periods pre- and post- TAU/CR phases),
and follow-up (2 months, 4 months, 6 months and 8
months following completion of a TAU/CR phase).
Attempts to improve follow-up rates in the current
study will include using telephone interviews and online
questionnaires at follow-up to administer some of the
assessments if necessary.
Primary outcome measures
Behavior Rating Inventory of Executive Function – Adult
Version (BRIEF-A) [55]
The BRIEF-A is a 75 item self-report questionnaire con-
sisting of nine subscales. The Global Executive Composite
(GEC) provides an overall summary score and will be a
primary outcome variable.
Time in treatment
Duration of treatment will be provided by the Alcohol
and Other Drug Treatment Services National Minimum
Data Set [56]. Time spent in treatment (length of stay)
as a proportion of program duration will be used as a
primary outcome variable.
Secondary outcome measures
Severity of Dependence Scale (SDS) [57]
The SDS is a 5-item questionnaire which assesses for se-
verity of substance use. The outcome variable will be
total score.
Health service utilisation
For each participant, the number of visits to health ser-
vices in the year prior to and following commencement of
CR will be compared. These data will be obtained from
linking data obtained from this study with four other data-
sets (NSW Admitted patient data collection, NSW Emer-
gency Department data collection, NSW Cause of death
unit record file, NSW mental health ambulatory data col-
lection). Data linkage will be undertaken by the Centre for
Health Record Linkage. Variables of interest will include
medical centre, hospital and emergency room admissions,
access of community-based mental health and AOD
services, and mortality rates.
Berry et al. BMC Psychiatry           (2019) 19:70 Page 5 of 11
Brief Executive Assessment Tool (BEAT) [58]
The BEAT is a screening tool developed to be sensitive
to executive dysfunction, particularly in a SUD popula-
tion. It includes both performance- and inventory-based
items. The outcome variable will be total score.
Stroop task [59]
In this measure of response inhibition, participants must
respond as quickly and accurately as possible across three
conditions. The first condition presents the words “red”,
“blue”, and “green”; the second presents patches of col-
ours; the third presents words printed in incongruent col-
ours and requires the participant to ignore the word and
say the colour. The outcome variable will be total score
on the third condition.
Five-point test [60]
The Five-Point Test assesses non-verbal figural fluency and
consists of producing novel designs under time constraints.
The task consists of a sheet of paper with 40 five-dot matri-
ces. Participants are asked to produce as many different fig-
ures as possible by connecting the dots within each
rectangle within 3 min. The outcome variable will be total
designs correctly completed.
Alpha span task [61]
The Alpha Span Task is a measure of working mem-
ory in which participants are read a list of words and
are asked to say the words back in alphabetical order.
The outcome variable will be the total alpha score.
Table 2 Timeline of Assessment Measures




Drug and Alcohol Cognitive Impairment
Screening Tool (DACIST)
X
Australian Treatment Outcomes Profile (ATOP) X Xa
Severity of Dependence Scale (SDS) X X X
Test of Premorbid Functioning X
Behaviour Rating Inventory of Executive
Functioning – Adult Version (BRIEF-A)
X X X
Kessler Psychological Distress Scale Plus (K10+) X X X
Quality of Life Enjoyment and Satisfaction
Questionnaire – Short Form (Q-LES-Q-SF)
X X X
Patient-Reported Outcomes Measurement
Information System Global 10 (PROMIS Global-10)
X X X
Brief Self-Control Scale X X X
EUROQOL – EQ-5D (EQ-5D) X X X
EUROHIS-QOL 8 X X X
Q-LES-Q-SF X X X
Alpha Span Task X X X
Symbol Digit Modalities Test (SDMT) X X X
Goal Attainment Scale 2.0 (GAS 2.0) X X X
Brief Executive Assessment Tool (BEAT) X X X
Stroop Task X X X
Five-Point Test X X X
Group Session Rating Scale X
Feasibility/satisfaction questionnaire (staff and clients) X
Time in Treatment (for individuals) X
Mean Length of Stay as a proportion of program
duration for sites
X X
Health Service Utilisation X
Economic Analysis X
Notes: a = Post-discharge follow-up only
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Symbol Digit Modalities Test (SDMT) [62]
The SDMT is a measure of processing speed in which
the participant writes a series of numbers corresponding
to symbols according to a symbol-number key at the top
of the page. The participant is asked to work through a
series of symbols as quickly as they can, with the out-
come variable the total number of symbols that can be
translated in 90 s.
Brief Self-Control Scale (BSCS) [63]
The BSCS is a 13-item self-report questionnaire that as-
sesses individual differences in the construct of self-control.
The outcome variable will be total score.
EUROQOL – EQ-5D-5L (EQ-5D) [64]
The EQ-5D is a 5-item measure of the quality of life that
can be used to calculate Quality Adjusted Life Years in
people with Substance Use Disorders. The outcome
measure will be total score.
EUROHIS-QOL 8-item index (EUROHIS-QOL 8) [65]
The EUROHIS-QOL 8 is an 8-item measure of the qual-
ity of life across four domains (physical, psychological,
environment, and social). Total QOL score will be the
outcome variable.
Quality of Life Enjoyment and Satisfaction Questionnaire –
Short Form (Q-LES-Q-SF) [66]
The Q-LES-Q-SF is a 16-item self-report questionnaire
that assesses quality of life across areas of daily function-
ing. Total score will be used as the outcome variable.
Patient-Reported Outcomes Measurement Information
System Global 10 (PROMIS Global 10) [67]
The PROMIS Global-10 consists of 10 items that
assess overall perceived quality of life (QOL), including
physical health, mental health, social health, pain and
fatigue. Total QOL score will be used as the outcome
variable.
Kessler Psychological Distress Scale Plus (K10+) [68]
The K10+ is a 14-item self-report measure that assesses
if a person has been affected by anxiety or depression
in the last four weeks. The outcome variable will be
total score.
Goal Attainment Scaling 2.0 (GAS 2.0) [69]
GAS 2.0 is a revised version of Goal Attainment Scaling
(GAS), a technique for quantifying the achievement (or
otherwise) of goals set [70]. GAS 2.0 was developed to
more objectively determine the level to which a client
has attained their goal. Whereas conventional GAS re-
quires the goal setter to estimate the likely outcome (pri-
mary goal) in advance, GAS 2.0 derives the primary goal
on the basis of: a) current level of functioning and b)
maximum realistic level of functioning. It makes use of a
goal menu to facilitate and expedite the process of goal
setting. The outcome variable will be post-TAU/CR GAS
score.
Australian Treatment Outcomes Profile (ATOP) [71]
The ATOP is a structured interview that has been vali-
dated to measure treatment outcomes in Australian drug
and alcohol populations. It contains two sections. Section
one details the quantity and frequency of substance use.
Section two details health and wellbeing variables such as
days in paid work/study, homelessness, eviction risk, vio-
lence and arrest, as well as ratings of psychological health,
physical health and overall quality of life. This measure
will be administered on intake, with participants asked to
respond to questions about their substance use, health
and wellbeing for the four-week period leading to their
commencement of residential rehabilitation. The measure
will also be administered at post-discharge follow up, with
participants asked to respond to questions about their
substance use, health and wellbeing in the previous four
weeks.
The following scale will be administered at the end of
each session during the CR phase:
Group Session Rating Scale (GSRS) [72]
The GSRS is a four-item visual analogue scale, designed
to be a brief clinical tool to measure group-therapy
alliance. The items are presented as bipolar anchors
requiring a response on a ten centimetre line. The scale
assesses aspects of individual’s perceptions of a group’s
therapeutic environment, including; 1) the relationship
between the leader and/or group, 2) goals and topics, 3)
acceptability of the approach, and 4) overall fit. GSRS
scores are obtained by measuring the marks made by
the client and summing the lengths to the nearest centi-
metre on each of the four lines. Scores are summed out
of a total possible score of 40. The total score will be the
process variable.
Economic analysis
An evaluation of the cost of delivering CR versus TAU
will be undertaken.
Intake measures
The following data will be gathered on intake in the
form of a structured questionnaire
1. Age;
2. Highest level of educational attainment;
3. Employment status;
4. Marital status;
5. Number of Children/Dependents
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6. Primary substance of misuse;
7. Years of regular use (by substance);
8. Nicotine Use
9. Use of OST
10. Relapses in residential treatment;
11. Relapses in community treatment;
12. Abstinence duration;
13. Country of birth
14. First language
15. Australian/Torres Strait Islander Status
16. Referral source (e.g. self-referred or
court-ordered enrolment)
Drug and Alcohol Cognitive Impairment Screening Tool
(DACIST) [73]
The DACIST was developed to measure self-reported his-
torical factors that may reasonably contribute to cognitive
impairment in a SUD population. Items assess history of
head injury, overdose, seizures, hospitalization, foetal drug
or alcohol exposure, neurological conditions, learning or
behavioural difficulties during schooling and subjective
appraisal of cognitive impairment.
Mini International Neuropsychiatric Interview V7.0.2 for
DSM-5 (MINI) [74]
The MINI is a structured interview used for assessing
indicators of DSM-5 diagnoses.
Statistical methods
Sample size estimation
The primary outcome is the BRIEF-A GEC difference
score between pre- and post-TAU/CR phase. Given pre-
vious data for a more comprehensive 24 h CR program
[42], sample size calculations were based on a difference
in BRIEF-A score of 2.25 for the current 12 h program.
We used the sample size methodology for stepped wedge
designs put forward by Hooper et al. [75]. Assuming a
standard deviation of 5.15, obtained from the Marceau
data [42], an individually randomised trial would require a
total sample of 165 people in order to have 80% power to
detect the intervention effect at the 5% significance level.
The design effect for cluster randomisation, assuming an
intraclass correlation of 0.05 and anticipating 20 people
per cluster, is 1.95 and the design effect for repeated as-
sessment, assuming a cluster autocorrelation of 0.5, is
0.534. The required number of clusters for this stepped
wedge design is therefore nine. In order to account for a
10% loss of the total sample to follow-up, (e.g participants
that are discharged and not replaced by new participants
in the research) and to protect against the possibility of a
cluster withdrawing from the trial, an additional cluster
will be recruited yielding a total of 10.
Analysis plan
Baseline characteristics will be summarised using means
and standard deviations or frequencies and percentages
as appropriate. The primary outcome variable will be the
BRIEF-A GEC score and the effect of the intervention
will be estimated using a linear mixed model. The model
will include the baseline BRIEF-A GEC as a covariate
and a fixed effect for each time period after baseline to
account for any secular trends. We will also include ran-
dom effects for treatment centre, time within centre and
individual within centre to account for the clustering, re-
peated measurements on centre and repeated measures
on individuals, respectively. The main predictor of inter-
est will be a pre−/post-intervention variable, which will
measure the overall effect of the intervention. The data
will be analysed according to the intent-to-treat principle,
with sensitivity analysis undertaken to include all partici-
pants under an appropriate multiple imputation model for
the missing data.
Two analyses are proposed to investigate the impact of
CR on treatment retention, being:
1. Direct analysis of retention (proportion of time
spent in treatment relative to program duration)
across TAU and CR conditions; and
2. Comparison of historical retention data (dating
back 2–5 years) with retention rates following the
first CR phase for each site. A 10% increase in
service retention rate will be the indicator of a
clinically meaningful gain.
Discussion
EF impairment is a significant predictor of treatment
drop-out for individuals with SUD. There is an oppor-
tunity for AOD treatment providers to address cogni-
tive impairment as part of routine care in order to
potentially increase treatment efficacy and reduce treat-
ment drop-out. The present study aims to examine the
effectiveness of providing a group-based compensatory
CR intervention as an adjunct to residential AOD treat-
ment programs. It is expected that compared to pre-
intervention, participants will demonstrate a significant
improvement in EF and the duration of treatment re-
tention. In addition, it is anticipated that there will be
reductions in harmful AOD use and associated health
service utilisation, as well as significant improvements
in personal goal achievement, quality of life, and treat-
ment satisfaction. As the current study is the first
stepped wedge cluster randomised trial of a compensa-
tory CR intervention within a residential AOD popula-
tion, the results potentially hold important implications
for the way that interventions are delivered across
treatment settings.
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Strengths and limitations
The current study is a large, multi-site, stepped wedge
cluster randomised trial that will be conducted across ten
residential treatment programs. The strength of conduct-
ing this type of “real world” research is that it is more rep-
resentative of actual clinical practice and helps to provide
some evidence regarding the feasibility of using these types
of interventions as part of ongoing routine care. The re-
search design also includes additional attempts to increase
the ecological validity of the results by using very inclusive
eligibility criteria, including individuals with previous trau-
matic brain injuries and psychiatric comorbidities.
Another strength of the study is that outcome measures
have been carefully chosen to reflect the effects of CR on
real-world functioning. Given that performance- and
inventory-based EF assessments are minimally correlated
and may assess distinct components of EF, the current
study aims to provide a comprehensive assessment of EF to
account for abilities that are likely to translate to functional
outcomes [36, 76]. This study will also be the first to evalu-
ate whether compensatory CR will result in improved treat-
ment retention, which has been shown to be an important
predictor of successful long-term outcomes for individuals
with SUD [3]. Furthermore, the current study will take
person-centred outcomes into account, including measure-
ments of AOD use, health service use, personal goal attain-
ment, quality of life, and treatment satisfaction. Inclusion of
person-centred outcomes will measure whether CR is likely
to result in contextually meaningful and desired treatment
outcomes. Finally, an economic analysis will be undertaken
to determine the cost of delivering CR versus TAU in resi-
dential treatment settings.
A significant challenge in this trial is the high rate of un-
planned drop-out that is common in residential AOD
treatment services. According to recent figures, approxi-
mately 20% of individuals with SUD unexpectedly cease
treatment [2]. To help address this concern, compensatory
CR will be delivered in one-hour sessions, twice a week,
over a six-week period, which is a reasonable amount of
time to expect individuals to dedicate to the intervention.
A further challenge will be retaining participants at
follow-up. Attempts to improve follow-up rates in the
current study include using telephone and online follow-
up to administer some outcome assessments, obtaining
contact details of significant others to help with locating
participants and reinforcing the importance of conducting
follow-up to participants.
The current study will be the first stepped wedge clus-
ter randomised trial of a compensatory CR intervention
in a residential substance abuse population. The study
seeks to address a significant gap in the literature by
examining the effectiveness of implementing a six-week
CR group program within AOD residential treatment
programs. It is expected that following completion of
CR, participants will demonstrate significantly improved
EF and treatment retention rates, reduced AOD use and
health service utilisation rates, as well as achievement of
individually-set goals, quality of life, and treatment
satisfaction.
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